Ezetimibe and Simvastatin Tablets, 10mg/40mg, 90-count bottle, Rx only, Manufactured by: Glenmark...

FDA Drug Recall #D-0462-2025 — Class III — May 19, 2025

Recall Summary

Recall Number D-0462-2025
Classification Class III — Low risk
Date Initiated May 19, 2025
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Glenmark Pharmaceuticals Inc., USA
Location Mahwah, NJ
Product Type Drugs
Quantity 6,759 Con - 90 bottle pack

Product Description

Ezetimibe and Simvastatin Tablets, 10mg/40mg, 90-count bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot No. 2, Phase-2, Pharma Zone SEZ, Madya Pradesh, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-323-90

Reason for Recall

Failed Impurities/Degradation Specifications: Out of Specification (OOS) for related substances test for Anhydro Simvastatin at the 06-month time point during long-term stability study.

Distribution Pattern

Nationwide USA and PR

Lot / Code Information

Lot #: 17240195, Exp 01/31/2026.

Other Recalls from Glenmark Pharmaceuticals Inc., USA

Recall # Classification Product Date
D-0246-2026 Class II Ondansetron Orally Disintegrating Tablets, USP,... Dec 30, 2025
D-0199-2026 Class III Bisoprolol Fumarate and Hydrochlorothiazide Tab... Nov 21, 2025
D-0222-2026 Class III Nebivolol Tablets, 20 mg, 90 Tablets, Rx Only, ... Nov 18, 2025
D-0662-2025 Class II Azelaic Acid Gel, 15%, 50 grams, For Topical Us... Sep 17, 2025
D-0021-2026 Class II Viorele, Desogestrel and Ethinyl Estradiol, USP... Sep 3, 2025

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.